nei THIS MONTH IN
PSYCHOPHARMACOLOGY
FDA Approves Ubrogepant for Acute Treatment of Migraine
January 24, 2020   

Schizophrenia is a lifelong illness affecting approximately 2.4 milliMigraine, an episodic neurologic condition encompassing headaches, sensitivity to light and sounds, and nausea, affects over 30 million individuals in the United States and is the 2nd leading cause of disability worldwide. Fortunately...
 Continue reading (Members only)
Psilocybin Receives Breakthrough Therapy Designation for Major Depressive Disorder
January 22, 2020   

The Food and Drug Administration (FDA) has granted psilocybin Breakthrough Therapy Designation for the second time. This latest FDA designation goes to...
 Continue reading (Members only)
FDA Approves Lumateperone for Schizophrenia in Adults
January 14, 2020   

Schizophrenia is a lifelong illness affecting approximately 2.4 million Americans and is characterized by psychotic, negative, cognitive, and affective symptoms. Although there are numerous antipsychotic agents available to treat schizophrenia, optimized treatment for the individual patient varies and...
 Continue reading
FDA Approves Lemborexant for Insomnia
January 9, 2020   

Although the exact reason is unknown, sleep is an essential component of both physical and mental health. Unfortunately, approximately 30% of adults suffer from insomnia -the inability to attain or maintain sleep despite adequate opportunity. Not only do insomnia sufferers have...
 Continue reading (Members only)
Genomic Relationships Across Eight Psychiatric Disorders
January 3, 2020   

There is evidence that pleotropic genes may influence the development of a range of psychiatric disorders, however the nature of these mechanisms has been unclear. In a recent meta-analysis across eight psychiatric disorders...
 Continue reading (Members only)
US FDA Requires Warning Regarding Risk of Respiratory Depression in Gabapentin/Pregabalin Label
December 20, 2019   

The US FDA is requiring that new warnings regarding risk of respiratory depression be added to the prescribing information for gabapentin and pregabalin...
 Continue reading (Members only)
Overdose Risk High Following Buprenorphine Discontinuation
December 13, 2019   

Opioid use disorder is a considerable issue in the United States. Medication assisted treatment (MAT) involves replacing opioids (such as hydrocodone or heroin) with agents that bind to the mu opioid receptor but do not elicit...
 Continue reading
Assessing Knowledge About Traumatic Brain Injury Within Intimate Partner Violence Survivor Providers
December 4, 2019   

Traumatic brain injury, as a result of intimate partner violence, has serious negative mental and physical health consequences, yet there is still a gap in understanding the impact of intimate partner violence on head trauma. In a recent 2-phase study...
 Continue reading (Members only)
Meta-analysis Shows No Effect of Omega-3 for Prevention or Treatment of Depression and Anxiety
November 25, 2019   

Many individuals suffering from mental health disorders, such as depression and anxiety, turn to the use of complementary and alternative medications (CAMs). One such CAM is polyunsaturated fatty acids...
 Continue reading (Members only)
Are Cannabinoids Useful in the Treatment of Mental Health Disorders?
November 21, 2019   

Despite the increased interest in use of CBD and THC in the treatment of mental health issues, there is little positive data available to recommend such treatments at this time..
 Continue reading
12345678910...
Top of Page